|
KMID : 1011720190120020085
|
|
International Journal of Thyroidology
2019 Volume.12 No. 2 p.85 ~ p.90
|
|
|
Updates of Radioiodine Treatment for Graves’ Disease
|
|
Jeong Shin-Young
|
|
|
Abstract
|
|
|
|
Radioiodine (RAI) has been used for the treatment of hyperthyroidism and is usually administered orally as sodium iodide (I-131) in solution or a capsule. However, this results in RAI being rapidly incorporated into the thyroid cells, and extensive local tissue damage occurring via beta emissions of I-131. The incidence rate of hypothyroidism is 5-50% at the first year after RAI therapy and is positively associated with the dosage of RAI. RAI has been used since 1960 in Korea; however, there have been few well-designed prospective trials, leaving many questions about indications, optimal dose, efficacy, and side-effects. This review summarizes the latest research pertaining to clinical questions about indications, optimal dose, efficacy, and side-effects.
|
|
|
KEYWORD
|
|
|
Radioactive iodine, Graves’ disease, Thyroid, Hyperthyroidism
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|
|